Radiotherapy-Activated NBTXR3 Shows Survival Benefit in Elderly Patients With Head and Neck Squamous Cell Carcinoma
October 26th 2021
The administration of NBTXR3 monotherapy activated by radiotherapy resulted in encouraging survival improvements in difficult-to-treat elderly and frail patients with locally advanced head and neck squamous cell carcinoma who are ineligible for cisplatin and intolerant to cetuximab.